In women undergoing intrauterine insemination after ovarian stimulation (OS-IUI) for the treatment of unexplained infertility, the use of gonadotropin vs other oral medications carries an increased risk of multiple gestation for every birth gained, as reported in a recent study.
The use of povidone iodine (PI) is more effective than chlorhexidine gluconate (CHG) at reducing vaginal bacterial colony counts in pregnancy and appears to be a superior vaginal antiseptic for decreasing postpartum infections, according to a study presented at the 2020 Annual Meeting of the Society for Maternal-Fetal Medicine (SMFM 2020).
Being of type O blood may increase the risk of postpartum haemorrhage (PPH) during caesarean delivery, according to a new study presented at the recently concluded 40th Annual Pregnancy Meeting of the Society for Maternal Foetal Medicine (SMFM 2020).
Heartburn during pregnancy and lactation should be managed with lifestyle modifications, and physicians must discuss with the patient risks and benefits of medications in cases where disease severity increases, according to a recent review.
Intravenous (IV) infusion of iron isomaltoside led to a significantly reduced incidence of hypophosphatemia in patients with iron deficiency anaemia (IDA) compared with ferric carboxymaltose, according to results of two randomized clinical trials.
A vegan diet among pregnant women appears to have no impact on the umbilical-cord levels of vitamin B12, folate, ferritin and haemoglobin, according to a study presented at the 2020 Annual Meeting of the Society for Maternal-Fetal Meeting (SMFM 2020).
Pregnant women with urinary tract infections (UTIs) caused by multidrug-resistant (MDR) bacteria may be at increased risk of developing pyelonephritis, according to a single-centre, retrospective study presented at SMFM 2020.
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.